956 related articles for article (PubMed ID: 29996082)
21. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity.
Billeskov R; Elvang TT; Andersen PL; Dietrich J
PLoS One; 2012; 7(6):e39909. PubMed ID: 22768165
[TBL] [Abstract][Full Text] [Related]
22. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
23. Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines.
Rozot V; Nemes E; Geldenhuys H; Musvosvi M; Toefy A; Rantangee F; Makhethe L; Erasmus M; Bilek N; Mabwe S; Finak G; Fulp W; Ginsberg AM; Hokey DA; Shey M; Gurunathan S; DiazGranados C; Bekker LG; Hatherill M; Scriba TJ;
Commun Biol; 2020 Oct; 3(1):563. PubMed ID: 33037320
[TBL] [Abstract][Full Text] [Related]
24. H4:IC31 Vaccine or BCG Revaccination for Tuberculosis.
de Bree C; van Crevel R; Netea MG
N Engl J Med; 2018 Nov; 379(20):1969. PubMed ID: 30428296
[No Abstract] [Full Text] [Related]
25. Designing tuberculosis vaccine efficacy trials - lessons from recent studies.
Ginsberg AM
Expert Rev Vaccines; 2019 May; 18(5):423-432. PubMed ID: 30892969
[TBL] [Abstract][Full Text] [Related]
26. H1:IC31 vaccination is safe and induces long-lived TNF-α
Mearns H; Geldenhuys HD; Kagina BM; Musvosvi M; Little F; Ratangee F; Mahomed H; Hanekom WA; Hoff ST; Ruhwald M; Kromann I; Bang P; Hatherill M; Andersen P; Scriba TJ;
Vaccine; 2017 Jan; 35(1):132-141. PubMed ID: 27866772
[TBL] [Abstract][Full Text] [Related]
27. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.
Dye C
J R Soc Interface; 2013 Oct; 10(87):20130365. PubMed ID: 23904584
[TBL] [Abstract][Full Text] [Related]
28. Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis.
Mahasha PW; Ndwandwe DE; Mavundza EJ; Shey M; Wiysonge CS
BMJ Open; 2019 Oct; 9(10):e027033. PubMed ID: 31619416
[TBL] [Abstract][Full Text] [Related]
29. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.
Andrews JR; Nemes E; Tameris M; Landry BS; Mahomed H; McClain JB; Fletcher HA; Hanekom WA; Wood R; McShane H; Scriba TJ; Hatherill M
Lancet Respir Med; 2017 Apr; 5(4):282-290. PubMed ID: 28215501
[TBL] [Abstract][Full Text] [Related]
30. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
Spertini F; Audran R; Chakour R; Karoui O; Steiner-Monard V; Thierry AC; Mayor CE; Rettby N; Jaton K; Vallotton L; Lazor-Blanchet C; Doce J; Puentes E; Marinova D; Aguilo N; Martin C
Lancet Respir Med; 2015 Dec; 3(12):953-62. PubMed ID: 26598141
[TBL] [Abstract][Full Text] [Related]
31. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection.
Lin PL; Dietrich J; Tan E; Abalos RM; Burgos J; Bigbee C; Bigbee M; Milk L; Gideon HP; Rodgers M; Cochran C; Guinn KM; Sherman DR; Klein E; Janssen C; Flynn JL; Andersen P
J Clin Invest; 2012 Jan; 122(1):303-14. PubMed ID: 22133873
[TBL] [Abstract][Full Text] [Related]
32. Current status of new tuberculosis vaccine in children.
Pang Y; Zhao A; Cohen C; Kang W; Lu J; Wang G; Zhao Y; Zheng S
Hum Vaccin Immunother; 2016 Apr; 12(4):960-70. PubMed ID: 27002369
[TBL] [Abstract][Full Text] [Related]
33. CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.
Masonou T; Hokey DA; Lahey T; Halliday A; Berrocal-Almanza LC; Wieland-Alter WF; Arbeit RD; Lalvani A; von Reyn CF
PLoS One; 2019; 14(5):e0217091. PubMed ID: 31120957
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
Deng YH; He HY; Zhang FJ
Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
[TBL] [Abstract][Full Text] [Related]
35. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices.
MMWR Recomm Rep; 1996 Apr; 45(RR-4):1-18. PubMed ID: 8602127
[TBL] [Abstract][Full Text] [Related]
36. Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis.
Clark S; Lanni F; Marinova D; Rayner E; Martin C; Williams A
J Infect Dis; 2017 Sep; 216(5):525-533. PubMed ID: 28329234
[TBL] [Abstract][Full Text] [Related]
37. Phase 2b Controlled Trial of M72/AS01
Van Der Meeren O; Hatherill M; Nduba V; Wilkinson RJ; Muyoyeta M; Van Brakel E; Ayles HM; Henostroza G; Thienemann F; Scriba TJ; Diacon A; Blatner GL; Demoitié MA; Tameris M; Malahleha M; Innes JC; Hellström E; Martinson N; Singh T; Akite EJ; Khatoon Azam A; Bollaerts A; Ginsberg AM; Evans TG; Gillard P; Tait DR
N Engl J Med; 2018 Oct; 379(17):1621-1634. PubMed ID: 30280651
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.
von Reyn CF; Lahey T; Arbeit RD; Landry B; Kailani L; Adams LV; Haynes BC; Mackenzie T; Wieland-Alter W; Connor RI; Tvaroha S; Hokey DA; Ginsberg AM; Waddell R
PLoS One; 2017; 12(5):e0175215. PubMed ID: 28498853
[TBL] [Abstract][Full Text] [Related]
39. Neonatal revaccination with Bacillus Calmette-Guérin elicits improved, early protection against Mycobacterium tuberculosis in mice.
Li W; Huang H; Hua W; Ben S; Liu H; Xu B; Xian Q; Tang Z; Shen H
Vaccine; 2012 May; 30(21):3223-30. PubMed ID: 22342709
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
Reither K; Katsoulis L; Beattie T; Gardiner N; Lenz N; Said K; Mfinanga E; Pohl C; Fielding KL; Jeffery H; Kagina BM; Hughes EJ; Scriba TJ; Hanekom WA; Hoff ST; Bang P; Kromann I; Daubenberger C; Andersen P; Churchyard GJ
PLoS One; 2014; 9(12):e114602. PubMed ID: 25490675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
